Clinical trial
A Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
NCT00301821 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2006
- Completion date
- April 30, 2015
- Enrollment
- 107 (actual)
- Sites
- 162
Conditions
As the registry lists them; a condition with its own page is linked.